Cargando…

When, how and why BRCA1 and BRCA2 genetic testing is offered to patients who do not meet standard criteria

Detalles Bibliográficos
Autores principales:	Duffy, J, Greening, S, Creighton, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327155/ http://dx.doi.org/10.1186/1897-4287-10-S2-A65

Ejemplares similares

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

Practical consensus recommendation on when to do BRCA testing
por: Parikh, Purvish M., et al.
Publicado: (2018)

BRCA1 testing in Lithuania
por: Janavicius, Ramunas
Publicado: (2012)

Haplotype analysis in German families with recurrent BRCA1 and BRCA2 mutations
por: Wappenschmidt, B, et al.
Publicado: (2001)

BRCA2 interacting proteins
por: Vidarsson, H, et al.
Publicado: (2000)

Breast cancer in young women: prevalence of LOH at p53, BRCA1 and BRCA2
por: Johnson, SM, et al.
Publicado: (2000)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
por: Bielecka, Helena, et al.
Publicado: (2012)

Mutational analysis of BRCA1 and BRCA2 genes in Spanish women with early-onset breast cancer
por: Martínez-Ferrandis, JI, et al.
Publicado: (2000)

Estrogen receptor transcription and transactivation: Genetic modifiers of cancer risks conferred by BRCA1 and BRCA2
por: Devilee, P
Publicado: (2001)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
por: Bielecka, Helena, et al.
Publicado: (2012)

Searching for BRCA3 by exome sequencing
por: Makunin, I, et al.
Publicado: (2012)

Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
por: Phillips, KA, et al.
Publicado: (2012)

A multi-center study to evaluate the impact of germline BRCA1 and BRCA2 mutations on ovarian cancer survival
por: Bolton, KL, et al.
Publicado: (2012)

Selenium and the risk of cancer in BRCA1 carriers
por: Lubinski, J, et al.
Publicado: (2011)

One test to identify 50% of all Norwegian BRCA1 mutations
por: Møller, P, et al.
Publicado: (2000)

Breast Cancer and Genetic BRCA1/2 Testing in Routine Clinical Practice: Why, When and For Whom?
por: Lux, Michael P., et al.
Publicado: (2023)

Molecular characterization of BRCA1 and BRCA2 genes in breast cancer patients under 40 years-old or with familiar cancer history
por: Millan, Silvia Vidal, et al.
Publicado: (2007)

The contribution of LARGE genomic rearrangements of BRCA1 and BRCA2 gene mutations in breast and ovarian cancer families in a clinical cohort
por: Sawyer, S, et al.
Publicado: (2012)

BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial
por: Kote-Jarai, Z, et al.
Publicado: (2000)

Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer
por: Kemp, Zoe, et al.
Publicado: (2019)

Expression profiling of BRCA1 associated breast tumors
por: Berns, EMJJ, et al.
Publicado: (2000)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Germline mutations of BRCA1-associated RING domain (BARD1) gene in breast and/or ovarian families negative for BRCA1 and 2 alterations
por: Ghimenti, C, et al.
Publicado: (2000)

Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness
por: de Bock, G H, et al.
Publicado: (2013)

Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer
por: Nilsson, Martin P., et al.
Publicado: (2017)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Selenium and genotypes as marker of risk in BRCA1 mutation carriers
por: Jaworska, K, et al.
Publicado: (2012)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations
por: Duffy, S W, et al.
Publicado: (2002)

Why do authors persist in submitting trial reports that do not meet the journal eligibility criteria or AllTrials standards?
por: Noyes, Jane
Publicado: (2023)

RAD21 overexpression is frequently observed in BRCA-X Prostate Cancers
por: Deb, S, et al.
Publicado: (2012)

Role of the breast cancer susceptibility gene BRCA1 in radio-resistance
por: Sylvain, V, et al.
Publicado: (2000)

Screening for BRCA1 gene mutations by capillary electrophoretic REF-SSCP
por: Kringen, P, et al.
Publicado: (2000)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

Vitamins A, E and D and cancer risk in BRCA1 carriers
por: Kąklewski, K, et al.
Publicado: (2012)

The curious case of a woman with two BRCA1 mutations in trans
por: Scott, Rodney J, et al.
Publicado: (2015)

Smoking cessation prior to elective plastic surgery: why, when and how?
por: Theocharidis, Vasileios, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_02k69m43nrn4btnim5i9hnh6pv